Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Go back to Agilent Receives EU Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma| Agilent Technologies Inc (NYSE: A) | Delayed: 146.85 -4.01 (2.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.86 | 52 Week High | $48.63 | |||
| Open | $148.02 | 52 Week Low | $34.15 | |||
| Day High | $149.22 | P/E | 67.99 | |||
| Day Low | $145.97 | EPS | $2.16 | |||
| Volume | 1,603,236 | |||||
